Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?

Description

This study is being conducted to see how people with Postural tachycardia syndrome (POTS) make sense of the things they see. The information may help doctors to learn more about how the different parts of people's brains communicate.

Conditions

Postural Tachycardia Syndrome

Talk to us

Study Overview

On this page

Study Details

Study overview

This study is being conducted to see how people with Postural tachycardia syndrome (POTS) make sense of the things they see. The information may help doctors to learn more about how the different parts of people's brains communicate.

Pediatric POTS: Does a Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?

Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?

Condition
Postural Tachycardia Syndrome
Intervention / Treatment

-

Contacts and Locations

Richmond

Virginia Commonwealth University, Richmond, Virginia, United States, 23298

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Females 12-21 years old
  • * Able to communicate and provide consent/assent
  • * English speaking
  • * Diagnosed with POTS (POTS will be defined standardly as a symptomatic ≥ 40 bpm rise in heart rate without a drop in blood pressure and with symptoms of orthostatic intolerance clinically)
  • * Age-matched healthy control subjects: no POTS or other neurological disorders
  • * Inflammatory arthritis, connective tissue or auto-immune disorder
  • * Any chronic neurological disorder besides POTS
  • * Evidence of unstable medical disorder, such as kidney (rising creatinine, or end-stage renal failure) or liver impairment (rising AST or ALT, or end-stage with coagulopathy), poorly controlled significant cardiovascular (CHF), respiratory, endocrine (diabetes - A1c \> 9 - or untreated thyroid dysfunction) or uncontrolled psychiatric illness (such as untreated depression, psychosis, etc.)
  • * Neuropathy, central nervous system disorder (e.g., Cerebral palsy, developmental delay, seizure disorder, MS, stroke, etc.)
  • * Treatment with a drug or medical device within the previous 30 days that has not received regulatory approval
  • * Use of hormones (except insulin, thyroid replacement or oral contraceptives, which will be carefully documented)
  • * Current substance or alcohol abuse
  • * Any major surgical intervention with general anesthesia in the last 60 days and minor procedure, such as tooth extraction, endoscopy, etc., with local or conscious sedation within 7 days
  • * Any on-going or pending medical, health or disability related litigation, or current pursuit of disability
  • * Any condition that in the judgment of the investigator would interfere with the patient's ability to provide informed consent, comply with study instructions, place the patient at increased risk, or which would clearly confound the interpretation of the study results (specific reason will be documented)
  • * Chronic use of narcotics for pain
  • * Claustrophobia or any metal hardware that may interfere with MRI
  • * Investigators and study staff

Ages Eligible for Study

12 Years to 21 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Virginia Commonwealth University,

Gisela Chelimsky, M.D., PRINCIPAL_INVESTIGATOR, Virginia Commonwealth University

Study Record Dates

2025-05